Find News

Filter articles

Showing 3411 to 3420 of 3607 results

US Supreme Court reverses Medtronic ruling


The US Supreme Court has ruled that when licensees seek a declaratory judgement of non-infringement, the patentee bears the burden of proof to show infringement.

Actavis survives challenge to birth control pill

US21-01-2014Legal developments

On January 17, Actavis confirmed that the US District Court for the District of New Jersey found its US patent 7,704,984, which covers Lo Loestrin Fe birth control pills, to be valid and infringed by Lupin and Amneal.

Federal Circuit rules against USPTO on Patent Term Adjustment case


The US Court of Appeals for the Federal Circuit has upheld a ruling which found that the US Patent and Trademark Office had been incorrectly calculating Patent Term Adjustment lengths.

Aurobindo to acquire Actavis’s European generic units

EU, India20-01-2014Mergers & acquisitions

Aurobindo’s European subsidiary is set to acquire Actavis’s commercial generic operations in seven Western European markets in a deal worth about €30 million ($40 million).

South African PR efforts spark drug controversy

South Africa17-01-2014

South African drug companies have been accused by advocacy organisations of planning a "deceptive" campaign to delay new laws which could see the introduction of more generic medicines.

HGF Limited adds to London office


UK IP firm HGF Limited has appointed Stephanie Loeffler as a partner in its London office.

Edwards awarded $394 million in heart valve case

US17-01-2014Legal developments

Edwards Lifesciences Corporation secured another victory against its transcatheter heart valve rival Medtronic, whose CoreValve product was found to wilfully infringe one of Edwards’ patents in a verdict handed down on January 15.

RPG domain name challenge backfires in WIPO ruling

India, US16-01-2014

Mumbai-based pharmaceutical company RPG Life Sciences Ltd has been found guilty of reverse domain name hijacking in a dispute fought at the WIPO’s Arbitration and Mediation Center.

Allergan win bars Sandoz’s Lumigan generic

US16-01-2014Legal developments

Drug company Sandoz, the generic arm of Novartis, may not market generic versions of Allergan’s eye drop solution Lumigan before the last patent covering it expires in 2027, a district court decided on January 14.

Potter Clarkson announces changes at the top


UK law firm Potter Clarkson LLP has made changes to its team with the appointment of two senior managers.

Showing 3411 to 3420 of 3607 results